Typhoid (Enteric) Fever - Management

1. Confirm diagnosis before/alongside starting treatment

• Blood culture is the mainstay (best yield in first week); stool/urine culture become more sensitive by week 2-3; bone marrow culture is most sensitive overall but rarely needed (Tintinalli's Emergency Medicine, p. 3385).
• Widal/rapid antigen tests are used in endemic settings but lack sensitivity/specificity - do not rely on them alone.

2. Empiric antibiotic therapy (uncomplicated disease)

• Ampicillin, TMP-SMX, and chloramphenicol are now unreliable in most regions due to widespread MDR strains.
• Fluoroquinolone resistance (nalidixic-acid-resistant strains) is rising, particularly in South/Southeast Asian isolates.
• Extensively drug-resistant (XDR) S. Typhi has caused a large ongoing epidemic in Pakistan since 2016 - resistant to ceftriaxone, ampicillin, ciprofloxacin, and TMP-SMX, leaving isolates susceptible only to azithromycin and carbapenems (Red Book 2021, Committee on Infectious Diseases, p. 1724; Harrison's 22E, p. 1359).
• CDC/AHA guidance: for suspected typhoid in patients with no travel history, or travel to Pakistan or Iraq, empiric therapy should be a carbapenem, azithromycin, or both; ceftriaxone remains reasonable empiric therapy for travel to other regions, with treatment adjusted once susceptibility results return.
• A 2024 systematic review of RCTs (Journal of Ayub Medical College) found oral azithromycin has efficacy comparable to or better than other antimicrobials across age groups for typhoid treatment (PMID: 39623850) - supporting its expanding first-line role, especially where resistance is a concern.

3. Severe / complicated disease

• If the patient is severely toxic, in shock, or has typhoid encephalopathy/meningitis, add dexamethasone to antibiotic therapy (Tintinalli's Emergency Medicine, p. 3387). Park's textbook similarly notes hydrocortisone 100 mg/day for 3-4 days in profoundly toxic patients.
• Complications requiring specific management: intestinal (small bowel) perforation - surgical management; GI hemorrhage - transfusion; DIC; myocarditis; cholecystitis; renal failure; relapse (can occur even after clinical improvement, usually with a milder course).
• Supportive care: IV fluid rehydration, antipyretics, blood transfusion if significant GI blood loss, nutritional support.

4. Isolation and infection control (hospital/public health)

• Enteric precautions - stool/urine are the sole sources of infection; disinfect with 5% cresol; soiled linen soaked in 2% chlorine; strict hand hygiene.
• Notification to public health authorities where mandatory.
• Isolate until three consecutive negative stool and urine cultures on separate days (Park's Textbook of PSM, p. 1487).

5. Chronic carrier state

• Identify via stool/urine culture, duodenal drainage (biliary S. Typhi), or Vi antibody testing (positive in ~80% of chronic carriers).
• Treatment: prolonged high-dose ampicillin or amoxicillin (4-6 g/day) plus probenecid (2 g/day) for 6 weeks - clears carriage in about 70% of cases. Chloramphenicol is ineffective for carriage.
• Cholecystectomy with concurrent ampicillin may be needed for carriers with gallstones/biliary carriage refractory to antibiotics.

6. Follow-up and prognosis

• Repeat stool/urine cultures 3-4 months after discharge and again at 12 months to detect carrier state.
• With early diagnosis and treatment, mortality drops to about 1%, versus roughly 10-30% untreated (Park's Textbook of PSM; Tintinalli's Emergency Medicine).

7. Prevention (relevant to management of outbreaks/exposed contacts)

• Typhoid conjugate vaccines (TCV) are now the preferred vaccine option, especially in endemic, pediatric populations. A 2025 Cochrane systematic review confirms efficacy of TCVs in preventing typhoid fever (PMID: 40326553), and a 2025 meta-analysis found good real-world effectiveness in children/adolescents (PMID: 41125003). Vaccination doesn't replace treatment but is central to outbreak control and pre-travel prophylaxis.